Physician profile
Patrick M Williams
NPI 1235217639
$1,786.82
in general payments reported to CMS, 2019-2025
24 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.42 · 2020: $70.73 · 2022: $14.96 · 2023: $430 · 2024: $715 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.72 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $270.92 | 2024-2025 | Trodelvy |
| Pfizer INC. | $173.32 | 2023-2025 | |
| Daiichi Sankyo INC. | $170.53 | 2023-2025 | Enhertu |
| Adc Therapeutics America, INC. | $124.74 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $108.99 | 2019-2023 | Opdivo |
| Incyte Corporation | $100.66 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Tempus Ai, INC | $96.57 | 2024 | |
| Lilly USA, LLC | $83.68 | 2023 | Retevmo |
| Janssen Biotech, INC. | $82.32 | 2023-2025 | Tecvayli, Erleada |
| Regeneron Healthcare Solutions, INC. | $76.22 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $74.20 | 2024-2025 | Ninlaro, Vpriv |
| Novartis Pharmaceuticals Corporation | $66.79 | 2020-2025 | |
| Stemline Therapeutics INC. | $60.17 | 2024-2025 | Orserdu, Elzonris |
| Glaxosmithkline, LLC. | $58.55 | 2024-2025 | Ojjaara |
| Celgene Corporation | $58.53 | 2019-2023 | Reblozyl |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.30 | 2023 | |
| Aveo Pharmaceuticals, INC. | $29.53 | 2024-2025 | |
| Amgen INC. | $21.25 | 2025 | Evenity |
| Rigel Pharmaceuticals, INC. | $19.78 | 2023 | Tavalisse, Rezlidhia |
| Ipsen Biopharmaceuticals, INC | $18.46 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $18.15 | 2024 | Krazati |
| Morphosys, US INC. | $15.50 | 2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $13.92 | 2023 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $13.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.